Beneficial activity of Enterococcus faecalis CECT7121 in the anti-lymphoma protective response

Abstract

Aims: To study the anti‐tumour effects of Enterococcus faecalis CECT7121 on LBC cells, an aggressive murine T‐cell lymphoma that kills the host in 18 days when is intraperitoneally (i.p.) administrated. Methods and Results: In vitro studies have shown that LBC cell proliferation was inhibited by Ent. faecalis CECT7121 stimulus in a dose‐dependent manner, inducing apoptosis. The production of ceramide was involved in the latter effect. To undertake in vivo studies, syngeneic BALB/c mice pre‐treated i.p. with Ent. faecalis CECT7121 (2·5 × 108 CFU) were challenged i.p. with LBC cells (1·0 × 106 cells) the day after. On day 30 post‐inoculation of LBC cells, 70% of Ent. faecalis CECT7121 pre‐treated mice survived, whereas no survivals were recorded in the control group. A group of surviving mice was re‐challenged with LBC cells, and 89% of them survived. Upon stimulation with irradiated LBC cells, spleen cell proliferation, high IFNγ, IL‐12 and IL‐10 levels were observed in surviving animals. Conclusions: Enterococcus faecalis CECT7121 affected multiple factors of the tumour establishment by the following methods: down‐regulating the LBC cell proliferation and inducing apoptosis in these cells; and enhancing the immune response that protects animals from lymphoma challenge and re‐challenge. Significance and Impact of the Study: This study demonstrate that Ent. faecalis CECT7121 has potential as a probiotic that could facilitate the development of novel complements to therapeutic strategies against oncological diseases.

Treatment with <i>Enterococcus faecalis</i> CECT7121 Is Not Effective as Therapy in Mice with an Established Allergy Status

“…The decrease in the anti-OVA IgG1/IgG2a ratios observed in the group of animals treated with the bacterium accounted for a rise in the levels of specific IgG2a. The latter finding is in line with the pro-Th1 activity already reported for E. faecalis CECT7121 [19] [21] [22].…”

Lentinula edodes-derived polysaccharide rejuvenates mice in terms of immune responses and gut microbiota

“…For example, Enterococcus faecalis is a typical probiotics, which has been shown to induce diverse beneficial activities in animal models, including the increased production of specific anti-Giardia intestinal IgA and blood IgG, 43 anti-lymphoma protective response, 44 prevention of ovalbumin-induced allergic response, 45 and suppression of Th17 cell development. The Euclidean distances (De) among 3 groups (N, O and Oa) are calculated as De(O, N) = 0.19, De(O, Oa) = 0.20, and De(N, Oa) = 0.10, i.e.…”

Polyphasic characterization of Enterococcus strains isolated from traditional Moghan cheese in Iran

“…A few strains are also being marketed as probiotics adjuncts, contributing to GIT health by improving the microbial balance following diarrhea or antibiotic associated diarrhea (Franz, Huch, Abriouel, Holzapfel, & Gálvez, ; Tarasova et al, ). Other beneficial effects of Entrococci include their antiviral activity (Wang et al, ), protective antitumor effect (Castro et al, ), ability to lower cholesterol by excretion of deconjugated bile salts (Guo, Li, Tang, Yang, & Huo, ), and immune modulation (Molina et al, ). Currently, the only species within the Enterococcus genus that are intended for use as probiotics in the human and animal are E. faecalis and Enterococcus faecium (Franz et al, ).…”